{"protocolSection": {"identificationModule": {"nctId": "NCT03961360", "orgStudyIdInfo": {"id": "HSC-MS-18-1073"}, "organization": {"fullName": "The University of Texas Health Science Center, Houston", "class": "OTHER"}, "briefTitle": "Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida", "officialTitle": "Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida: An Open Label, Comparative Effectiveness, Randomized Controlled Trial (ASPREO Trial)", "acronym": "ASPREO"}, "statusModule": {"statusVerifiedDate": "2024-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-05-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-04-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-04-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-16", "studyFirstSubmitQcDate": "2019-05-21", "studyFirstPostDateStruct": {"date": "2019-05-23", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2024-04-10", "resultsFirstSubmitQcDate": "2024-04-10", "resultsFirstPostDateStruct": {"date": "2024-05-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-04-10", "lastUpdatePostDateStruct": {"date": "2024-05-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Farah Hassan Amro", "investigatorTitle": "Clinical Fellow OBGYN", "investigatorAffiliation": "The University of Texas Health Science Center, Houston"}, "leadSponsor": {"name": "The University of Texas Health Science Center, Houston", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg/day aspirin."}, "conditionsModule": {"conditions": ["Pre-Eclampsia", "Hypertension in Pregnancy", "Obesity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 220, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "162 mg/day Aspirin", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Aspirin 162 mg"]}, {"label": "81 mg/day Aspirin", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Aspirin 81 mg"]}], "interventions": [{"type": "DRUG", "name": "Aspirin 81 mg", "description": "Low dose aspirin was initially reported as having a beneficial effect at preeclampsia", "armGroupLabels": ["81 mg/day Aspirin"]}, {"type": "DRUG", "name": "Aspirin 162 mg", "description": "Low dose aspirin was initially reported as having a beneficial effect at preeclampsia", "armGroupLabels": ["162 mg/day Aspirin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis", "description": "based on American College Obstetrics and Gynecology (ACOG) guidelines", "timeFrame": "3-7 months"}], "secondaryOutcomes": [{"measure": "Maternal Outcomes- Number of Participants Who Delivered Due to Preeclampsia With Severe Features", "timeFrame": "less than 37 weeks gestational age (GA)"}, {"measure": "Maternal Outcomes-Number of Participants With Gestational Hypertension", "description": "development of hypertension anytime during pregnancy based on ACOG guidelines", "timeFrame": "3-7 months"}, {"measure": "Maternal Outcomes- Number of Participants With Placenta Abruption", "description": "Placental abruption occurs when the placenta separates from the inner wall of the uterus before birth. As assessed by treating OBGYN", "timeFrame": "1 day"}, {"measure": "Maternal Outcomes- Number of Participants With Eclampsia", "description": "onset of seizures (convulsions) in a woman with pre-eclampsia per ACOG guidelines", "timeFrame": "20 weeks"}, {"measure": "Maternal Outcomes- Number of Participants With HELLP Syndrome", "description": "group of symptoms that occur in pregnant women who have: hemolysis(H): (the breakdown of red blood cells)elevated liver enzymes (EL). low platelet (LP) count. Assessed by ACOG guidelines and measured in urine and blood samples", "timeFrame": "4 weeks"}, {"measure": "Maternal Outcomes- Number of Participants With Postpartum Hemorrhage", "description": "excessive bleeding following the birth of a baby", "timeFrame": "1-24 hrs post delivery"}, {"measure": "Maternal Outcomes- Number of Participants With Other Maternal Bleeding", "description": "any other bleeding associated with birth not otherwise categorized", "timeFrame": "during labor to 24 hrs post delivery"}, {"measure": "Maternal Outcomes- Number of Participants That Required Blood Transfusion", "description": "peripartum", "timeFrame": "during delivery"}, {"measure": "Neonatal Outcome- Gestational Age at Delivery", "timeFrame": "at delivery"}, {"measure": "Neonatal Outcomes-Delivery at < 37 Weeks", "timeFrame": "at delivery"}, {"measure": "Neonatal Outcomes-Apgar Score < 5 at 5 Minutes", "description": "The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome.", "timeFrame": "5 minutes post delivery"}, {"measure": "Neonatal Outcome-Small for Gestational Age", "description": "Small for gestational age (SGA) means that a fetus or an infant is smaller or less developed than normal for the baby's sex and gestational age. Small for gestational age (SGA) is defined as a birth weight that is below the 10th percentile.", "timeFrame": "at delivery"}, {"measure": "Neonatal Outcome-Neonatal Intensive Care Unit (NICU) Length of Stay", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)"}, {"measure": "Neonatal Outcome- Number of Participants With Intraventricular Hemorrhage Grade III-IV", "description": "bleeding inside or around the ventricles in the brain.", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)"}, {"measure": "Neonatal Outcome-Number of Participants With Bronchopulmonary Dysplasia", "description": "chronic lung disease that affects newborns (mostly premature) and infants.", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)"}, {"measure": "Neonatal Outcome-Number of Participants With Necrotizing Enterocolitis", "description": "medical condition where a portion of the bowel dies", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* A singleton gestation at less than 20 weeks at time of enrollment, with a BMI greater than or equal to 30 and one of the following:\n\n  1. History of preeclampsia in a prior pregnancy\n* Diagnosis will be obtained by review of records, and if unavailable then patient history. Preeclampsia diagnosis may be made in antepartum or postpartum period.\n\nOR 2. At least stage I hypertension during pregnancy\n\n* Stage I hypertension is defined as a systolic blood pressure between 130- 139 mm Hg or diastolic blood pressure between 80-89 mm Hg21\n* This blood pressure criteria is met regardless of medication usage\n* The patient must have a blood pressure reading \u2265 130-139/80-89 mm Hg at least during 1 clinic visit during the current pregnancy; before or at time of enrollment\n\nOR\n\n3. Pre-gestational diabetes\n\n* Type 1 and Type 2 diabetics are included\n* Gestational diabetes mellitus diagnosed prior to 20 weeks gestational age will also be included\n\nExclusion Criteria\n\n* Known allergy/prior adverse reaction/any medical condition where aspirin is contraindicated\n* Already on aspirin prior to pregnancy\n* Baseline renal Disease\n* Baseline proteinuria identified at time of enrollment, defined as urine analysis with 3+ protein, or urine protein to creatinine ratio \u2265 0.3\n* Systemic Lupus Erythematosus\n* Seizure disorder on medications\n* HIV positive status\n* Known major fetal anomalies\n* Multifetal gestation", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "farah Amro, MD", "affiliation": "University of Texas Health Science Center of Houston", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "The University of Texas Health Science Center at Houston", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "FG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "110"}, {"groupId": "FG001", "numSubjects": "110"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "107"}, {"groupId": "FG001", "numSubjects": "102"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "BG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "220"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30", "lowerLimit": "26", "upperLimit": "34"}, {"groupId": "BG001", "value": "29", "lowerLimit": "25", "upperLimit": "33"}, {"groupId": "BG002", "value": "29", "lowerLimit": "25", "upperLimit": "34"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "220"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "African American", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "111"}]}, {"title": "Hispanic/Latina", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "59"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Unknown or not reported", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "35"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "110"}, {"groupId": "BG001", "value": "110"}, {"groupId": "BG002", "value": "220"}]}]}]}, {"title": "Insurance Type", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Private", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Government assisted (Medicaid, Medicare or other federal or state funded assistance program)", "measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "198"}]}, {"title": "Self pay", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Gestational age at enrollment", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "weeks", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15.9", "lowerLimit": "13.6", "upperLimit": "17.6"}, {"groupId": "BG001", "value": "15.6", "lowerLimit": "13.6", "upperLimit": "17.7"}, {"groupId": "BG002", "value": "15.64", "lowerLimit": "13.57", "upperLimit": "17.71"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37", "lowerLimit": "33", "upperLimit": "43"}, {"groupId": "BG001", "value": "38", "lowerLimit": "34", "upperLimit": "44"}, {"groupId": "BG002", "value": "37.88", "lowerLimit": "33.60", "upperLimit": "43.73"}]}]}]}, {"title": "Number of Participants who are Nulliparous", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Number of Participants with Systemic Lupus Erythematosus", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Number of Participants who use tobacco during pregnancy", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "History of preeclampsia in prior pregnancy", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "67"}]}]}]}, {"title": "Number of participants with Type 1 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Number of participants with type 2 diabetes", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "84"}]}]}]}, {"title": "Number of participants diagnosed with gestational diabetes before 20 weeks", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Number of participants enrolled prior to 16 weeks", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "113"}]}]}]}, {"title": "Number of participants on aspirin prior to enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "44"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis", "description": "based on American College Obstetrics and Gynecology (ACOG) guidelines", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "3-7 months", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "41"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants Who Delivered Due to Preeclampsia With Severe Features", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "less than 37 weeks gestational age (GA)", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes-Number of Participants With Gestational Hypertension", "description": "development of hypertension anytime during pregnancy based on ACOG guidelines", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "3-7 months", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "20"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants With Placenta Abruption", "description": "Placental abruption occurs when the placenta separates from the inner wall of the uterus before birth. As assessed by treating OBGYN", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "1 day", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants With Eclampsia", "description": "onset of seizures (convulsions) in a woman with pre-eclampsia per ACOG guidelines", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "20 weeks", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants With HELLP Syndrome", "description": "group of symptoms that occur in pregnant women who have: hemolysis(H): (the breakdown of red blood cells)elevated liver enzymes (EL). low platelet (LP) count. Assessed by ACOG guidelines and measured in urine and blood samples", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants With Postpartum Hemorrhage", "description": "excessive bleeding following the birth of a baby", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "1-24 hrs post delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants With Other Maternal Bleeding", "description": "any other bleeding associated with birth not otherwise categorized", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during labor to 24 hrs post delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Maternal Outcomes- Number of Participants That Required Blood Transfusion", "description": "peripartum", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome- Gestational Age at Delivery", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "weeks", "timeFrame": "at delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36.30", "lowerLimit": "34.40", "upperLimit": "37.40"}, {"groupId": "OG001", "value": "37.20", "lowerLimit": "35.10", "upperLimit": "38.20"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcomes-Delivery at < 37 Weeks", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "at delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "45"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcomes-Apgar Score < 5 at 5 Minutes", "description": "The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "5 minutes post delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome-Small for Gestational Age", "description": "Small for gestational age (SGA) means that a fetus or an infant is smaller or less developed than normal for the baby's sex and gestational age. Small for gestational age (SGA) is defined as a birth weight that is below the 10th percentile.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "at delivery", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome-Neonatal Intensive Care Unit (NICU) Length of Stay", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "days", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10", "lowerLimit": "4", "upperLimit": "17"}, {"groupId": "OG001", "value": "10.5", "lowerLimit": "3.75", "upperLimit": "21.5"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome- Number of Participants With Intraventricular Hemorrhage Grade III-IV", "description": "bleeding inside or around the ventricles in the brain.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome-Number of Participants With Bronchopulmonary Dysplasia", "description": "chronic lung disease that affects newborns (mostly premature) and infants.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Neonatal Outcome-Number of Participants With Necrotizing Enterocolitis", "description": "medical condition where a portion of the bowel dies", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "from birth until discharge from NICU (about 1 to 4 weeks)", "groups": [{"id": "OG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}, {"id": "OG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From enrollment (12 to 20.6 weeks gestational age) to 6 weeks post-partum", "eventGroups": [{"id": "EG000", "title": "162 mg/Day Aspirin", "description": "Aspirin 162 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia", "deathsNumAffected": 0, "deathsNumAtRisk": 110, "seriousNumAffected": 24, "seriousNumAtRisk": 110, "otherNumAffected": 51, "otherNumAtRisk": 110}, {"id": "EG001", "title": "81 mg/Day Aspirin", "description": "Aspirin 81 mg: Low dose aspirin was initially reported as having a beneficial effect at preeclampsia", "deathsNumAffected": 0, "deathsNumAtRisk": 110, "seriousNumAffected": 19, "seriousNumAtRisk": 110, "otherNumAffected": 61, "otherNumAtRisk": 110}], "seriousEvents": [{"term": "Placenta Abruption", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 110}]}, {"term": "Postpartum hemorrhage", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 110}]}, {"term": "Maternal blood transfusion", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 110}]}, {"term": "Fetal Heart Defect", "organSystem": "Congenital, familial and genetic disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}, {"term": "Kidney Malformation", "organSystem": "Congenital, familial and genetic disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 110}]}], "otherEvents": [{"term": "Preeclampsia", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 37, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 110}]}, {"term": "Gestational hypertension", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 110}]}, {"term": "Necrotizing Enterocolitis", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 110}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 110}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Farah Amro, MD", "organization": "The University of Texas Health Science Center at Houston", "email": "farah.h.amro@uth.tmc.edu", "phone": "713-500-6421"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2024-03-08", "uploadDate": "2024-04-09T13:34", "filename": "Prot_SAP_000.pdf", "size": 935790}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000011225", "term": "Pre-Eclampsia"}, {"id": "D000004461", "term": "Eclampsia"}, {"id": "D000046110", "term": "Hypertension, Pregnancy-Induced"}], "ancestors": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000011248", "term": "Pregnancy Complications"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}], "browseLeaves": [{"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M14106", "name": "Pre-Eclampsia", "asFound": "Pre-Eclampsia", "relevance": "HIGH"}, {"id": "M25635", "name": "Hypertension, Pregnancy-Induced", "asFound": "Hypertension in Pregnancy", "relevance": "HIGH"}, {"id": "M7633", "name": "Eclampsia", "asFound": "Eclampsia", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "T2019", "name": "Eclampsia", "asFound": "Eclampsia", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001241", "term": "Aspirin"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058633", "term": "Antipyretics"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Baseline", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}